1
|
Studer E, Nilsson S, Westman A, Pedersen NL, Eriksson E. Significance and Interrelationship of the Symptoms Listed in the DSM Criteria for Premenstrual Dysphoric Disorder. PSYCHIATRIC RESEARCH AND CLINICAL PRACTICE 2023; 5:105-113. [PMID: 37711753 PMCID: PMC10499188 DOI: 10.1176/appi.prcp.20220007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2022] [Revised: 03/01/2023] [Accepted: 03/21/2023] [Indexed: 09/16/2023] Open
Abstract
Objective While premenstrual dysphoric disorder (PMDD) as defined in DSM has become an established diagnosis, and a formal indication for drug treatment, the relative impact of the disparate symptoms named in the criteria, and to what extent they indeed constitute parts of one syndrome, remains insufficiently clarified. We have therefore explored the frequency, impact, and inter-relationship of different PMDD symptoms. Method Using a web survey, 10,457 Swedish women of fertile age were asked to retrospectively assess if they experience reduced functioning due to symptoms clearly associated with the premenstrual phase. Those responding affirmatively reported presence, severity, and impact of each symptom named in the PMDD criteria. Result Nine percent reported impairing premenstrual symptoms. Whereas irritability was reported to cause impairment in 77% of those passing the gate questions, somatic symptoms were common but seldom causing impairment. A vast majority reported presence of at least 5 different symptoms, as required to meet the PMDD criteria, but few reported each of 5 different symptoms to be severe or impairing. An analysis of the association between symptoms revealed clear-cut clustering of somatic and mood symptoms, respectively. Conclusion While retrospective account suggested irritability to be the clinically most important premenstrual symptom, some of the complaints named in the PMDD criteria were not or only weakly associated with mood symptoms and also reported to be of limited clinical significance. It is concluded that regarding all symptoms listed in the DSM criteria as clinically relevant manifestations of one and the same syndrome may be questioned.
Collapse
Affiliation(s)
- Erik Studer
- Department of PharmacologyInstitute of Neuroscience and Physiology at the Sahlgrenska AcademyUniversity of GothenburgGothenburgSweden
| | - Staffan Nilsson
- Institute of Mathematical SciencesChalmers University of TechnologyGothenburgSweden
| | - Anna Westman
- Department of PharmacologyInstitute of Neuroscience and Physiology at the Sahlgrenska AcademyUniversity of GothenburgGothenburgSweden
| | - Nancy L. Pedersen
- Department of Medical Epidemiology and BiostatisticsKarolinska InstitutetStockholmSweden
| | - Elias Eriksson
- Department of PharmacologyInstitute of Neuroscience and Physiology at the Sahlgrenska AcademyUniversity of GothenburgGothenburgSweden
| |
Collapse
|
2
|
Kaiser G, Janda C, Kleinstäuber M, Weise C. Clusters of premenstrual symptoms in women with PMDD: Appearance, stability and association with impairment. J Psychosom Res 2018; 115:38-43. [PMID: 30470315 DOI: 10.1016/j.jpsychores.2018.10.004] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/03/2018] [Revised: 09/17/2018] [Accepted: 10/12/2018] [Indexed: 11/17/2022]
Abstract
Although premenstrual dysphoric disorder (PMDD) is assumed to be a homogenous diagnostic entity, it is hallmarked by highly diverse clinical symptoms. In this study, we investigate symptom clusters in women prospectively diagnosed with severe premenstrual syndrome (PMS) or PMDD using factor analysis; analyze the stability of the structures of different symptom patterns and their association with impairment at work, in recreation, and in relationships. A total of 174 prospective symptom diaries were analyzed with principal axis factoring revealing six clusters named affective dysphoria, somatic dysphoria, irritability, breast/body sensitivity, pain, and eating behavior. Cronbach's alpha was good for all clusters (0.83 to 0.91) with the exception of the cluster pain (0.69). Clusters of symptoms appeared to be stable between two consecutive menstrual cycles (except of pain and eating behavior) and between two cycles with a waiting period of eight weeks in between. Multiple regression analyses showed different associations of the clusters with impairment. Somatic dysphoria was the cluster most strongly associated with impairment. The results indicate that in severe PMS/PMDD, different symptom patterns should be considered. As the risk of impairment differs between symptom clusters, individual treatment options should be considered and further investigated in research and treatment.
Collapse
Affiliation(s)
- Gudrun Kaiser
- Division of Clinical Psychology and Psychotherapy, Department of Psychology, Philipps-University of Marburg, Marburg, Germany.
| | - Carolyn Janda
- Division of Clinical Psychology and Psychotherapy, Department of Psychology, Philipps-University of Marburg, Marburg, Germany
| | - Maria Kleinstäuber
- Faculty of Medical and Health Sciences, School of Medicine, University of Auckland, New Zealand
| | - Cornelia Weise
- Division of Clinical Psychology and Psychotherapy, Department of Psychology, Philipps-University of Marburg, Marburg, Germany
| |
Collapse
|
3
|
Reid RL, Soares CN. Premenstrual Dysphoric Disorder: Contemporary Diagnosis and Management. JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA 2017; 40:215-223. [PMID: 29132964 DOI: 10.1016/j.jogc.2017.05.018] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2017] [Accepted: 05/04/2017] [Indexed: 11/17/2022]
Abstract
Most ovulatory women experience premenstrual symptoms (premenstrual syndrome, molimina) which indicate impending menstruation and are of little clinical relevance because they do not affect quality of life. A few women, however, experience significant physical and/or psychological symptoms before menstruation that, if left untreated, would result in deterioration in functioning and relationships. The precise etiology remains elusive, although new theories are gaining support in pre-clinical and early clinical trials. Refined diagnostic criteria allow better discrimination of this condition from other psychiatric diagnoses and the selection of symptom appropriate therapies that afford relief for most women. Pharmacotherapies (particularly selective serotonin reuptake inhibitors and SNRIs) represent the first-line treatment for premenstrual dysphoric disorder and severe, mood-related premenstrual syndrome. Continuous combined oral contraceptives have limited evidence for usefulness in premenstrual dysphoric disorder, whereas medical ovarian suppression is often recommended for patients who fail to respond or cannot tolerate first-line treatments (e.g., selective serotonin reuptake inhibitors). The use of cognitive behavioural therapies is promising, but it remains limited by sparse data and restricted access to trained professionals. A proper diagnosis (particularly the distinction from other underlying psychiatric conditions) is crucial for the implementation of effective therapy and alleviation of this impairing condition.
Collapse
Affiliation(s)
- Robert L Reid
- Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Queen's University School of Medicine, Kingston, ON.
| | - Claudio N Soares
- Department of Psychiatry, Queen's University School of Medicine, Kingston, ON
| |
Collapse
|
4
|
Lorenz TK, Gesselman AN, Vitzthum VJ. Variance in Mood Symptoms Across Menstrual Cycles: Implications for Premenstrual Dysphoric Disorder. ACTA ACUST UNITED AC 2017; 4:77-88. [PMID: 29201937 DOI: 10.1080/23293691.2017.1326248] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Premenstrual dysphoric disorder (PMDD) remains a controversial diagnosis: Some authors have argued that it pathologizes normal mood changes, and others have questioned the need for daily mood reports across multiple cycles. In the present study, we examined changes in mood among psychologically healthy young participants with regular menstrual cycles. We collected daily reports of negative mood (depression, nervousness, irritability, and fatigue) across two to six consecutive cycles from 27 participants aged 18-35 years, and we used variance decomposition analyses to examine how much of the variance in these daily reports was due to day, cycle, and individual. The majority of variance (79%-98%) was due to daily fluctuations and did not conform to a standard pattern of premenstrual rise/postmenstrual fall. These findings suggest that PMDD is not simply an exaggeration of mood patterns typical for psychologically healthy people. Individual patterns were relatively stable from cycle to cycle; thus tracking deviations from a patient's own normative mood patterns may have greater clinical utility than deviation from a presumptive norm.
Collapse
Affiliation(s)
- Tierney K Lorenz
- Department of Psychological Science, University of North Carolina at Charlotte, Charlotte, North Carolina, USA.,Women's Immunity and Sexual Health Lab, University of North Carolina at Charlotte, Charlotte, North Carolina, USA.,Kinsey Institute, Indiana University, Bloomington, Indiana, USA.,Center for Integrative Study of Animal Behavior, Indiana University, Bloomington, Indiana, USA
| | | | - Virginia J Vitzthum
- Center for Integrative Study of Animal Behavior, Indiana University, Bloomington, Indiana, USA.,Department of Anthropology, Indiana University, Bloomington, Indiana, USA.,Evolutionary Anthropology Laboratory, Indiana University, Bloomington, Indiana, USA
| |
Collapse
|
5
|
Reuveni I, Dan R, Segman R, Evron R, Laufer S, Goelman G, Bonne O, Canetti L. Emotional regulation difficulties and premenstrual symptoms among Israeli students. Arch Womens Ment Health 2016; 19:1063-1070. [PMID: 27538401 DOI: 10.1007/s00737-016-0656-y] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/29/2015] [Accepted: 08/12/2016] [Indexed: 12/21/2022]
Abstract
Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome (PMS) reported to affect 3-8 % of women of reproductive age and resulting in marked emotional and occupational impairment. Despite its prevalence, the etiology of PMDD is largely unknown, and patients remain mostly undiagnosed and poorly treated. It has been suggested that PMDD is a manifestation of underlying depressive disorder which is associated with the inability to regulate emotions in an adaptive manner. Therefore, we hypothesized that women with PMDD would exhibit increased difficulty with emotional regulation. A total of 648 female Israeli college students were assessed by the Premenstrual Symptoms Screening Tool (PSST) and the Difficulties in Emotion Regulation Scale (DERS). Of these women, 166 (25.6 %) met the criteria for PMS. Sixty-four (9.9 %) suffered from PMDD. More emotion regulation deficits were observed in the PMDD and PMS groups compared to the control group. Furthermore, there were more emotional regulation deficits among the predominantly psychological and mixed symptom subtype compared to the predominantly physical symptom subtype group. This is the first study to report an association between emotional dysregulation and PMDD. These findings may lead to development of more individually tailored treatment protocols focused on improving emotional regulation techniques.
Collapse
Affiliation(s)
- Inbal Reuveni
- Department of Psychiatry, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
| | - Rotem Dan
- MRI/MRS Lab, The Human Biology Research Center, Department of Medical Biophysics, Hadassah Hebrew University Medical Center, Jerusalem, Israel.,Edmond and Lily Safra Center for Brain Sciences (ELSC), The Hebrew University of Jerusalem, Jerusalem, Israel
| | - Ronen Segman
- Department of Psychiatry, Hadassah Hebrew University Medical Center, Jerusalem, Israel
| | - Ron Evron
- Department of Psychiatry, Hadassah Hebrew University Medical Center, Jerusalem, Israel
| | - Sofia Laufer
- Department of Psychiatry, Hadassah Hebrew University Medical Center, Jerusalem, Israel
| | - Gadi Goelman
- MRI/MRS Lab, The Human Biology Research Center, Department of Medical Biophysics, Hadassah Hebrew University Medical Center, Jerusalem, Israel
| | - Omer Bonne
- Department of Psychiatry, Hadassah Hebrew University Medical Center, Jerusalem, Israel
| | - Laura Canetti
- Department of Psychiatry, Hadassah Hebrew University Medical Center, Jerusalem, Israel.,Department of Psychology, Hebrew University, Jerusalem, Israel
| |
Collapse
|
6
|
Kumari S, Sachdeva A. Patterns and Predictors of Premenstrual Symptoms among Females Working in a Psychiatry Hospital. SCIENTIFICA 2016; 2016:6943852. [PMID: 27293977 PMCID: PMC4884805 DOI: 10.1155/2016/6943852] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/26/2015] [Accepted: 04/17/2016] [Indexed: 06/06/2023]
Abstract
Introduction. Premenstrual syndrome presents with vague psychological, somatic, or biological symptoms. It may be seen more commonly in a specific profile of patients. We try to evaluate the patterns and predictors of premenstrual symptoms among females working in a tertiary care psychiatry hospital. Methodology. We recruited working females at a tertiary care psychiatry hospital in India, through purposive sampling, and assessed them cross-sectionally. Premenstrual Symptom Checklist was used to assess the frequency and distribution of premenstrual symptoms, which were correlated with various sociodemographic variables to evaluate the predictors for premenstrual symptoms. Results. 150 working females were included, belonging to different sociodemographic profile. Somatic symptoms (backache, joint and muscles pain, and fatiguability) were most commonly reported followed by psychological (irritability and losing temper easily) and biological symptoms (increased micturition). Premenstrual symptoms were seen more commonly in women with higher educational status and nursing profession and residing in nuclear families (p < 0.05), while age and marital status did not correlate significantly. Discussion. Premenstrual symptoms are common and distressing, especially for working females. Somatic symptoms such as backache and joint pains predominate over psychobiological symptoms. Women with higher educational status and professions like nursing belonging to nuclear families are more prone to these symptoms. Attention needs to be given to premenstrual symptoms in such population of working females.
Collapse
Affiliation(s)
- Sunita Kumari
- Department of Psychiatry and Drug De-Addiction, Post Graduate Institute of Medical Education and Research, Dr. Ram Manohar Lohia Hospital, Park Street, New Delhi 110001, India
| | - Ankur Sachdeva
- Department of Psychiatry, ESIC Medical College and Hospital, NH-3, NIT, Faridabad, Haryana 121001, India
| |
Collapse
|
7
|
Ducasse D, Jaussent I, Olié E, Guillaume S, Lopez-Castroman J, Courtet P. Personality Traits of Suicidality Are Associated with Premenstrual Syndrome and Premenstrual Dysphoric Disorder in a Suicidal Women Sample. PLoS One 2016; 11:e0148653. [PMID: 26863007 PMCID: PMC4749223 DOI: 10.1371/journal.pone.0148653] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2015] [Accepted: 01/21/2016] [Indexed: 11/22/2022] Open
Abstract
Objective Both Premenstrual Syndrome (PMS) and Premenstrual Dysphoric Disorder (PMDD) might increase the risk of suicidal behavior. The aim of this study was to assess the relationship between personality dimensions specifically involved in suicidal vulnerability and PMS/PMDD. Method We collected data from 232 women consecutively hospitalized after a suicide attempt. We examined the relationship between impulsivity, aggressiveness/hostility, hopelessness, trait anger, affect intensity, emotional lability, and PMS/PMDD. Notably, we created an algorithm from the shortened Premenstrual Assessment form in order to assess PMDD status. Results The proportions of PMS and PMDD among female suicide attempters were 50% and 23% respectively. Women with PMS or PMDD were more likely to endorse most of these personality traits to than those without even after controlling for potential confounders. We found an impulsive-aggressive pattern of personality in women with PMS or PMDD, independently from the time of the menstrual cycle. Interestingly, trait anger remained associated with both PMS and PMDD independently of every other personality traits. The higher the anger level, the higher the risk was to suffer from both PMS and PMDD. Conclusions This study demonstrates a strong, independent association between PMS/PMDD and trait anger among a representative sample of female suicide attempters. It is of major interest for clinicians in view of addressing a substantial public health problem among women of reproductive age.
Collapse
Affiliation(s)
- Déborah Ducasse
- Department of Psychiatric Emergency & Acute Care, Lapeyronie Hospital, CHU Montpellier, Montpellier, France
- Inserm U1061, University of Montpellier UM1, Montpellier, France
- Fondamental Foundation, Créteil, France
- * E-mail:
| | | | - Emilie Olié
- Department of Psychiatric Emergency & Acute Care, Lapeyronie Hospital, CHU Montpellier, Montpellier, France
- Inserm U1061, University of Montpellier UM1, Montpellier, France
- Fondamental Foundation, Créteil, France
| | - Sébastien Guillaume
- Department of Psychiatric Emergency & Acute Care, Lapeyronie Hospital, CHU Montpellier, Montpellier, France
- Inserm U1061, University of Montpellier UM1, Montpellier, France
- Fondamental Foundation, Créteil, France
| | - Jorge Lopez-Castroman
- Department of Psychiatric Emergency & Acute Care, Lapeyronie Hospital, CHU Montpellier, Montpellier, France
- Inserm U1061, University of Montpellier UM1, Montpellier, France
- Fondamental Foundation, Créteil, France
| | - Philippe Courtet
- Department of Psychiatric Emergency & Acute Care, Lapeyronie Hospital, CHU Montpellier, Montpellier, France
- Inserm U1061, University of Montpellier UM1, Montpellier, France
- Fondamental Foundation, Créteil, France
| |
Collapse
|
8
|
Experimental reduction of pain catastrophizing modulates pain report but not spinal nociception as verified by mediation analyses. Pain 2015; 156:1477-1488. [DOI: 10.1097/j.pain.0000000000000192] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
9
|
Oral E, Kirkan TS, Yildirim A, Kotan Z, Cansever Z, Ozcan H, Aliyev E, Gulec M. Serum brain-derived neurotrophic factor differences between the luteal and follicular phases in premenstrual dysphoric disorder. Gen Hosp Psychiatry 2015; 37:266-72. [PMID: 25799087 DOI: 10.1016/j.genhosppsych.2015.03.001] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/25/2013] [Revised: 01/30/2015] [Accepted: 03/05/2015] [Indexed: 02/06/2023]
Abstract
OBJECTIVE We hypothesized that comparison of the serum brain-derived neurotrophic factor (BDNF) levels between women with premenstrual dysphoric disorder (PMDD) and women without PMDD in the luteal and follicular phases of their menstrual cycles would reflect the altered neuromodulator responses that compensate the underlying pathogenesis in PMDD. METHOD Twenty-nine participants without PMDD and 20 with PMDD were enrolled in the study. The serum BDNF, estrogen and progesterone levels were assessed at the follicular and luteal phases in their two consecutive menstrual cycles. RESULTS Participants with PMDD had significantly higher luteal serum BDNF levels than the control subjects. The serum BDNF levels were significantly higher in the luteal phase than in the follicular phase in women with PMDD. The difference in the serum BDNF levels between the luteal and follicular phases were significantly higher in the PMDD patients than in the control. CONCLUSIONS The higher serum BDNF levels in the luteal phase in the PMDD patients may reflect compensatory process that results in subsequent improvement of the PMDD-associated depressive symptoms in the follicular phase. The higher difference in the serum BDNF levels between the phases in PMDD patients may reflect an altered neuromodulator response.
Collapse
Affiliation(s)
- Elif Oral
- Department of Psychiatry, Medical Faculty, Ataturk University, Erzurum, Turkey.
| | - Tulay Sati Kirkan
- Department of Psychiatry, Erzurum Regional Training and Research Hospital, Erzurum, Turkey
| | - Abdulkadir Yildirim
- Department of Biochemistry, Medical Faculty, Ataturk University, Erzurum, Turkey
| | - Zerrin Kotan
- Department of Biochemistry, Pharmacy Faculty, Ataturk University, Erzurum, Turkey
| | - Zeliha Cansever
- Department of Medical Education, Medical Faculty, Ataturk University, Erzurum, Turkey
| | - Halil Ozcan
- Department of Psychiatry, Medical Faculty, Ataturk University, Erzurum, Turkey
| | - Elvin Aliyev
- Department of Biochemistry, Medical Faculty, Ataturk University, Erzurum, Turkey
| | - Mustafa Gulec
- Department of Psychiatry, Medical Faculty, Katip Celebi University, İzmir, Turkey
| |
Collapse
|
10
|
Farrar D, Neill J, Scally A, Tuffnell D, Marshall K. Is objective and accurate cognitive assessment across the menstrual cycle possible? A feasibility study. SAGE Open Med 2015; 3:2050312114565198. [PMID: 26770760 PMCID: PMC4679227 DOI: 10.1177/2050312114565198] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2014] [Accepted: 12/02/2014] [Indexed: 12/03/2022] Open
Abstract
Objectives: Variation in plasma hormone levels influences the neurobiology of brain regions involved in cognition and emotion processing. Fluctuations in hormone levels across the menstrual cycle could therefore alter cognitive performance and wellbeing; reports have provided conflicting results, however. The aim of this study was to assess whether objective assessment of cognitive performance and self-reported wellbeing during the follicular and luteal phases of the menstrual cycle is feasible and investigate the possible reasons for variation in effects previously reported. Methods: The Cambridge Neuropsychological Test Automated Battery and Edinburgh Postnatal Depression Scale were used to assess the cognitive performance and wellbeing of 12 women. Data were analysed by self-reported and hormone-estimated phases of the menstrual cycle. Results: Recruitment to the study and assessment of cognition and wellbeing was without issue. Plasma hormone and peptide estimation showed substantial individual variation and suggests inaccuracy in self-reported menstrual phase estimation. Conclusion: Objective assessment of cognitive performance and self-assessed wellbeing across the menstrual cycle is feasible. Grouping data by hormonal profile rather by self-reported phase estimation may influence phase-mediated results. Future studies should use plasma hormone and peptide profiles to estimate cycle phase and group data for analyses.
Collapse
Affiliation(s)
- Diane Farrar
- Bradford Institute for Health Research, Bradford Royal Infirmary, Bradford, UK
| | - Jo Neill
- Manchester Pharmacy School, Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK
| | - Andy Scally
- School of Allied Health Professions and Sport, Faculty of Health Studies, University of Bradford, Bradford, UK
| | - Derek Tuffnell
- Bradford Women's and Newborn Unit, Bradford Royal Infirmary, Bradford, UK
| | - Kay Marshall
- Manchester Pharmacy School, Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK
| |
Collapse
|
11
|
Goldberg JF. Is there life after diagnostic death? Aust N Z J Psychiatry 2014; 48:1167-8. [PMID: 25410629 DOI: 10.1177/0004867414559137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Joseph F Goldberg
- Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, USA
| |
Collapse
|
12
|
Affective disturbance associated with premenstrual dysphoric disorder does not disrupt emotional modulation of pain and spinal nociception. Pain 2014; 155:2144-52. [PMID: 25139588 DOI: 10.1016/j.pain.2014.08.011] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2014] [Revised: 07/31/2014] [Accepted: 08/12/2014] [Indexed: 11/23/2022]
Abstract
In healthy individuals, emotions modulate pain and spinal nociception according to a valence linear trend (ie, pain/nociception is highest during negative emotions and lowest during positive emotions). However, emerging evidence suggests that emotional modulation of pain (but not spinal nociception) is disrupted in fibromyalgia and disorders associated with chronic pain risk (eg, major depression, insomnia). The present study attempted to extend this work and to examine whether women with premenstrual dysphoric disorder (PMDD), a cyclical syndrome associated with debilitating affective symptoms during the late-luteal (premenstrual) phase of the menstrual cycle, is also associated with disrupted emotional modulation of pain. To do so, an affective picture-viewing procedure was used to study emotional modulation of pain and spinal nociception in 14 women with PMDD and 14 control women during mid-follicular, ovulatory, and late-luteal phases of the menstrual cycle (verified by salivary hormone levels and luteinizing hormone tests). At each phase, mutilation, neutral, and erotic pictures were presented to manipulate emotion. During picture viewing, suprathreshold electrocutaneous stimuli were presented to evoke pain and the nociceptive flexion reflex (NFR; a physiological measure of spinal nociception). Statistically powerful linear mixed model analyses confirmed that pictures evoked the intended emotional states in both groups across all menstrual phases. Furthermore, emotion modulated pain and NFR according to a valence linear trend in both groups and across all menstrual phases. Thus, PMDD-related affective disturbance is not associated with a failure to emotionally modulate pain, suggesting that PMDD does not share this pain phenotype with major depression, insomnia, and fibromyalgia.
Collapse
|
13
|
Frye CA, Koonce CJ, Walf AA. Novel receptor targets for production and action of allopregnanolone in the central nervous system: a focus on pregnane xenobiotic receptor. Front Cell Neurosci 2014; 8:106. [PMID: 24782710 PMCID: PMC3988369 DOI: 10.3389/fncel.2014.00106] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2014] [Accepted: 03/25/2014] [Indexed: 12/05/2022] Open
Abstract
Neurosteroids are cholesterol-based hormones that can be produced in the brain, independent of secretion from peripheral endocrine glands, such as the gonads and adrenals. A focus in our laboratory for over 25 years has been how production of the pregnane neurosteroid, allopregnanolone, is regulated and the novel (i.e., non steroid receptor) targets for steroid action for behavior. One endpoint of interest has been lordosis, the mating posture of female rodents. Allopregnanolone is necessary and sufficient for lordosis, and the brain circuitry underlying it, such as actions in the midbrain ventral tegmental area (VTA), has been well-characterized. Published and recent findings supporting a dynamic role of allopregnanolone are included in this review. First, contributions of ovarian and adrenal sources of precursors of allopregnanolone, and the requisite enzymatic actions for de novo production in the central nervous system will be discussed. Second, how allopregnanolone produced in the brain has actions on behavioral processes that are independent of binding to steroid receptors, but instead involve rapid modulatory actions via neurotransmitter targets (e.g., γ-amino butyric acid-GABA, N-methyl-D-aspartate- NMDA) will be reviewed. Third, a recent focus on characterizing the role of a promiscuous nuclear receptor, pregnane xenobiotic receptor (PXR), involved in cholesterol metabolism and expressed in the VTA, as a target for allopregnanolone and how this relates to both actions and production of allopregnanolone will be addressed. For example, allopregnanolone can bind PXR and knocking down expression of PXR in the midbrain VTA attenuates actions of allopregnanolone via NMDA and/or GABAA for lordosis. Our understanding of allopregnanolone’s actions in the VTA for lordosis has been extended to reveal the role of allopregnanolone for broader, clinically-relevant questions, such as neurodevelopmental processes, neuropsychiatric disorders, epilepsy, and aging.
Collapse
Affiliation(s)
- Cheryl A Frye
- Department of Psychology, The University at Albany-SUNY Albany, NY, USA ; Department of Biological Sciences, The University at Albany-SUNY Albany, NY, USA ; The Centers for Neuroscience, The University at Albany-SUNY Albany, NY, USA ; Life Sciences Research, The University at Albany-SUNY Albany, NY, USA ; Department of Chemistry and Biochemistry, The University of Alaska-Fairbanks Fairbanks, AK, USA ; Institute of Arctic Biology, The University of Alaska-Fairbanks Fairbanks, AK, USA ; IDeA Network of Biomedical Excellence (INBRE), The University of Alaska-Fairbanks Fairbanks, AK, USA
| | - Carolyn J Koonce
- Department of Psychology, The University at Albany-SUNY Albany, NY, USA ; Institute of Arctic Biology, The University of Alaska-Fairbanks Fairbanks, AK, USA ; IDeA Network of Biomedical Excellence (INBRE), The University of Alaska-Fairbanks Fairbanks, AK, USA
| | - Alicia A Walf
- Department of Psychology, The University at Albany-SUNY Albany, NY, USA ; Institute of Arctic Biology, The University of Alaska-Fairbanks Fairbanks, AK, USA ; IDeA Network of Biomedical Excellence (INBRE), The University of Alaska-Fairbanks Fairbanks, AK, USA
| |
Collapse
|
14
|
Junghaenel DU, Schneider S, Stone AA, Christodoulou C, Broderick JE. Ecological validity and clinical utility of Patient-Reported Outcomes Measurement Information System (PROMIS®) instruments for detecting premenstrual symptoms of depression, anger, and fatigue. J Psychosom Res 2014; 76:300-6. [PMID: 24630180 PMCID: PMC4162640 DOI: 10.1016/j.jpsychores.2014.01.010] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/09/2013] [Revised: 01/28/2014] [Accepted: 01/31/2014] [Indexed: 12/13/2022]
Abstract
OBJECTIVE This study examined the ecological validity and clinical utility of NIH Patient Reported-Outcomes Measurement Information System (PROMIS®) instruments for anger, depression, and fatigue in women with premenstrual symptoms. METHODS One-hundred women completed daily diaries and weekly PROMIS assessments over 4weeks. Weekly assessments were administered through Computerized Adaptive Testing (CAT). Weekly CATs and corresponding daily scores were compared to evaluate ecological validity. To test clinical utility, we examined if CATs could detect changes in symptom levels, if these changes mirrored those obtained from daily scores, and if CATs could identify clinically meaningful premenstrual symptom change. RESULTS PROMIS CAT scores were higher in the pre-menstrual than the baseline (ps<.0001) and post-menstrual (ps<.0001) weeks. The correlations between CATs and aggregated daily scores ranged from .73 to .88 supporting ecological validity. Mean CAT scores showed systematic changes in accordance with the menstrual cycle and the magnitudes of the changes were similar to those obtained from the daily scores. Finally, Receiver Operating Characteristic (ROC) analyses demonstrated the ability of the CATs to discriminate between women with and without clinically meaningful premenstrual symptom change. CONCLUSIONS PROMIS CAT instruments for anger, depression, and fatigue demonstrated validity and utility in premenstrual symptom assessment. The results provide encouraging initial evidence of the utility of PROMIS instruments for the measurement of affective premenstrual symptoms.
Collapse
|
15
|
Klatzkin RR, Bunevicius A, Forneris CA, Girdler S. Menstrual mood disorders are associated with blunted sympathetic reactivity to stress. J Psychosom Res 2014; 76:46-55. [PMID: 24360141 PMCID: PMC3951307 DOI: 10.1016/j.jpsychores.2013.11.002] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/07/2013] [Revised: 10/30/2013] [Accepted: 11/02/2013] [Indexed: 01/04/2023]
Abstract
OBJECTIVE Few studies have directly compared women with a menstrually related mood disorder (MRMD) with women who have suffered from depression for stress reactivity phenotypes. It is unclear whether blunted responses to stress in women with a MRMD reflect a unique phenotype of MRMDs or may be explained by a history of depression. METHODS We assessed cardiovascular reactivity to stress in four groups: 1) Women with a MRMD without a history of depression (n=37); 2) women with a MRMD plus a history of depression (n=26); 3) women without a MRMD and without a history of depression (n=43); and 4) women without a MRMD but with a history of depression (n=20). RESULTS Women with a MRMD showed blunted myocardial (heart rate and cardiac index) reactivity to mental stress compared to non-MRMD women, irrespective of histories of depression. Hypo-reactivity to stress predicted greater premenstrual symptom severity in the entire sample. Women with a MRMD showed blunted norepinephrine and diastolic blood pressure stress reactivity relative to women with no MRMD, but only when no history of depression was present. Both MRMD women and women with depression histories reported greater negative subjective responses to stress relative to their non-MRMD and never depressed counterparts. CONCLUSION Our findings support the assertion that a blunted stress reactivity profile represents a unique phenotype of MRMDs and also underscore the importance of psychiatric histories to stress reactivity. Furthermore, our results emphasize the clinical relevance of myocardial hypo-reactivity to stress, since it predicts heightened premenstrual symptom severity.
Collapse
Affiliation(s)
| | - Adomas Bunevicius
- Department of Psychiatry, University of North Carolina at Chapel Hill, North Carolina, USA
| | - Catherine A. Forneris
- Department of Psychiatry, University of North Carolina at Chapel Hill, North Carolina, USA
| | - Susan Girdler
- Department of Psychiatry, University of North Carolina at Chapel Hill, North Carolina, USA
| |
Collapse
|
16
|
Luteal serum BDNF and HSP70 levels in women with premenstrual dysphoric disorder. Eur Arch Psychiatry Clin Neurosci 2013; 263:685-93. [PMID: 23455589 DOI: 10.1007/s00406-013-0398-z] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/21/2012] [Accepted: 02/19/2013] [Indexed: 12/16/2022]
Abstract
Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome characterized by psychological and somatic symptoms commencing in the luteal phase of the menstrual cycle and concludes with menstrual bleeding. PMDD affects 3-8 % of premenopausal women and represents a significant public health problem especially in young women. Decreased brain-derived neurotrophic factor (BDNF) levels are associated with several mental disorders. Heat-shock protein-70 (HSP70) is an important member of the molecular chaperone system, which provides a molecular defense against proteotoxic stress. We hypothesized that there would be changed levels of BDNF and HSP70 in women with PMDD compared with non-symptomatic women, reflecting impaired and/or activated stress-related responses involved in the underlying pathogenesis of PMDD. Female medical students were screened, and 24 women without premenstrual symptoms and 25 women with PMDD were enrolled in the study. Psychiatric evaluation and the Daily Record of Severity of Problems-Short Form were used for two consecutive menstrual cycles to diagnose PMDD. Serum BDNF and HSP70 levels were assessed in the third luteal phase. Participants with PMDD had significantly higher serum BDNF and HSP70 levels compared with controls, and there was a significant positive correlation between serum BDNF and HSP70 levels. Increased HSP70 levels may reflect cellular distress in PMDD. Increased serum BDNF levels in the luteal phase in subjects with PMDD may reflect a compensation process, which results in subsequent improvement of PMDD-associated depressive symptoms in the follicular phase. Thus, increased serum BDNF levels may be indicative of a compensating capacity in PMDD.
Collapse
|
17
|
Accortt EE, Kogan AV, Allen JJ. Personal history of major depression may put women at risk for premenstrual dysphoric symptomatology. J Affect Disord 2013; 150:1234-7. [PMID: 23800446 PMCID: PMC3759648 DOI: 10.1016/j.jad.2013.05.091] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/20/2013] [Accepted: 05/31/2013] [Indexed: 11/19/2022]
Abstract
BACKGROUND Premenstrual dysphoric disorder (PMDD) is a chronic condition that significantly affects a woman's well-being on a monthly basis. Although co-occurrence of PMDD and major depressive disorder (MDD) is common, most studies examine whether women with PMDD are at risk for depression and investigations of PMDD in depressed women are scant. Therefore, the present study examined rates of PMDD in young depressed women. METHODS PMDD was assessed using a structured clinical interview (SCID-PMDD) in a sample of 164 young women with (n=85) and without (n=79) any history of depression. RESULTS Rates of PMDD were elevated among women with MDD in this sample. This result held true regardless of participants' MDD status (current, lifetime or past history-only symptoms of MDD) and regardless of whether all or most DSM-IV-TR PMDD criteria were met. LIMITATIONS Sample size in the present study was relatively small, and daily diary data were not available to confirm a PMDD diagnosis. CONCLUSIONS The current study highlights the need for clinicians to assess for PMDD in young female patients with major depression. Depressed women experiencing the added physical and psychological burden of PMDD may have a more severe disease course, and future studies will need to identify appropriate treatments for this subset of depressed women.
Collapse
Affiliation(s)
- Eynav E. Accortt
- University of California, Los Angeles, USA
- Corresponding authors. Dr. Accortt is to be contacted at Department of Psychology, University of California, Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA 90095-1563, United States. Tel.: +1 310-825-2248. Dr. Allen, Department of Psychology, University of Arizona, 1503 E. University Ave., room 312, Tucson, AZ 85721-0068, United States. , (E.E. Accortt), (J.J.B. Allen)
| | | | - John J.B. Allen
- University of Arizona, Tucson, USA
- Corresponding authors. Dr. Accortt is to be contacted at Department of Psychology, University of California, Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA 90095-1563, United States. Tel.: +1 310-825-2248. Dr. Allen, Department of Psychology, University of Arizona, 1503 E. University Ave., room 312, Tucson, AZ 85721-0068, United States. , (E.E. Accortt), (J.J.B. Allen)
| |
Collapse
|
18
|
Steiner M, Li T. Luteal phase and symptom-onset dosing of SSRIs/SNRIs in the treatment of premenstrual dysphoria: clinical evidence and rationale. CNS Drugs 2013; 27:583-9. [PMID: 23728922 DOI: 10.1007/s40263-013-0069-7] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Premenstrual dysphoria (PMD) affects 3-8 % of women in their reproductive years worldwide. This paper summarizes the studies establishing the efficacy of continuous, luteal phase, and symptom-onset dosing of selective serotonin reuptake inhibitors (SSRIs) and dual serotonin and norepinephrine reuptake inhibitors (SNRIs) in treating women with PMD. The evidence indicates that for some women, symptom-onset dosing with escitalopram, fluoxetine, and paroxetine controlled release (CR) is as effective as continuous or luteal phase dosing. The wide range of clinical efficacy of SSRIs/SNRIs suggests that they exert their therapeutic effect through multiple pathways. This paper offers a few alternative mechanisms of action to explain the rapid response to SSRIs/SNRIs in women with PMD.
Collapse
Affiliation(s)
- Meir Steiner
- Women's Health Concerns Clinic, St. Joseph's Healthcare, 301 James Street South, Hamilton, ON, L8P 3B6, Canada.
| | | |
Collapse
|
19
|
Haley CL, Sung SC, Rush AJ, Trivedi MH, Wisniewski SR, Luther JF, Kornstein SG. The clinical relevance of self-reported premenstrual worsening of depressive symptoms in the management of depressed outpatients: a STAR*D report. J Womens Health (Larchmt) 2013; 22:219-29. [PMID: 23480315 DOI: 10.1089/jwh.2011.3186] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
OBJECTIVE To determine the incidence, clinical and demographic correlates, and relationship to treatment outcome of self-reported premenstrual exacerbation of depressive symptoms in premenopausal women with major depressive disorder who are receiving antidepressant medication. METHOD This post-hoc analysis used clinical trial data from treatment-seeking, premenopausal, adult female outpatients with major depression who were not using hormonal contraceptives. For this report, citalopram was used as the first treatment step. We also used data from the second step in which one of three new medications were used (bupropion-SR [sustained release], venlafaxine-XR [extended release], or sertraline). Treatment-blinded assessors obtained baseline treatment outcomes data. We hypothesized that those with reported premenstrual depressive symptom exacerbation would have more general medical conditions, longer index depressive episodes, lower response or remission rates, and shorter times-to-relapse with citalopram, and that they would have a better outcome with sertraline than with bupropion-SR. RESULTS At baseline, 66% (n=545/821) of women reported premenstrual exacerbation. They had more general medical conditions, more anxious features, longer index episodes, and shorter times-to-relapse (41.3 to 47.1 weeks, respectively). Response and remission rates to citalopram, however, were unrelated to reported premenstrual exacerbation. Reported premenstrual exacerbation was also unrelated to differential benefit with sertraline and bupropion-SR. CONCLUSIONS Self-reported premenstrual exacerbation has moderate clinical utility in the management of depressed patients, although it is not predictive of overall treatment response. Factors that contribute to a more chronic or relapsing course may also play a role in premenstrual worsening of major depressive disorder (MDD).
Collapse
|
20
|
Futterman LA. Advances in the diagnosis of premenstrual syndrome and premenstrual dysphoric disorder. ACTA ACUST UNITED AC 2013; 4:91-8. [PMID: 23496112 DOI: 10.1517/17530050903431418] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Premenstrual disorders negatively impact the quality of life and functional ability of millions of women. The two generally recognized premenstrual disorders are premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD). These disorders are characterized by a wide variety of nonspecific mood, somatic and behavioral symptoms that occur only during the late luteal phase of a woman's cycle and disappear soon after the onset of menstruation. This paper reviews the diagnostic criteria for PMS and PMDD, describes some of the more common symptom diaries and other tools used to diagnose premenstrual disorders, and discusses the challenges inherent in diagnosing PMS and PMDD. A survey of peer-reviewed articles and relevant texts provided diagnostic criteria, descriptions of diagnostic tools and information about diagnostic challenges. The many nonspecific symptoms associated with premenstrual disorders complicate the diagnostic process. The use of proven symptom diaries and other diagnostic tools should aid in the differential diagnosis of premenstrual disorders. Patients need to report bothersome premenstrual symptoms, and clinicians should become more proficient in the diagnostic process in order to prevent underdiagnosis of these disorders.
Collapse
Affiliation(s)
- Lori A Futterman
- University of California San Diego, Department of Psychiatry, 591 Camino de la Reina, Suite 705, San Diego, CA 92108, USA +1 619 297 3311 ; +1 619 294 3322 ;
| |
Collapse
|
21
|
Pilver CE, Libby DJ, Hoff RA. Premenstrual dysphoric disorder as a correlate of suicidal ideation, plans, and attempts among a nationally representative sample. Soc Psychiatry Psychiatr Epidemiol 2013; 48:437-46. [PMID: 22752111 PMCID: PMC3774023 DOI: 10.1007/s00127-012-0548-z] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/25/2012] [Accepted: 06/19/2012] [Indexed: 01/08/2023]
Abstract
PURPOSE Suicide is a major public health concern and a leading cause of death in the United States. Psychopathology is an established risk factor for non-fatal suicidal behavior; however, it is unclear whether premenstrual dysphoric disorder (PMDD), a psychiatric disorder specific to women, is correlated with these outcomes. The objective of this study was to determine if PMDD status was associated with suicidal ideation, plans, and attempts, independent of socio-demographic factors and psychiatric comorbidity. METHODS We conducted a secondary data analysis of 3,965 American women aged 18-40 who participated in the Collaborative Psychiatric Epidemiology Survey. Descriptive statistics and forward stepwise logistic regression modeling were performed using SUDAAN software. RESULTS The prevalence of non-fatal suicidal behaviors increased in a graded fashion according to PMDD status. Although the control for demographic characteristics and psychiatric comorbidity greatly attenuated the unadjusted association between PMDD and suicidal behaviors, women with PMDD remained significantly more likely than women with no premenstrual symptoms to report suicidal ideation (OR 2.22; 95% CI 1.40-3.53), plans (OR 2.27; 95% CI 1.20-4.28), and attempts (OR 2.10; 95% CI 1.08-4.08). Only the likelihood of suicidal ideation was significantly elevated among women with moderate/severe premenstrual syndrome (PMS; OR 1.49; 95% CI 1.17-1.88), compared to women with no premenstrual symptoms. CONCLUSIONS PMDD was strongly and independently associated with non-fatal suicidal behaviors among a nationally representative sample. These findings suggest that clinicians treating women with PMDD should assess and be vigilant for signs of non-fatal suicidal behavior, and that clinicians should evaluate and treat the premenstrual symptoms of women who express these behaviors.
Collapse
Affiliation(s)
- Corey E. Pilver
- Yale School of Public Health, Division of Biostatistics, Yale University, New Haven, CT 06510, USA
| | | | - Rani A. Hoff
- VISN 1 MIRECC, VA CT Healthcare System, West Haven, CT, USA,Department of Psychiatry, Yale University, New Haven, CT, USA
| |
Collapse
|
22
|
Cosgrove L, Wheeler EE. Drug firms, the codification of diagnostic categories, and bias in clinical guidelines. THE JOURNAL OF LAW, MEDICINE & ETHICS : A JOURNAL OF THE AMERICAN SOCIETY OF LAW, MEDICINE & ETHICS 2013; 41:644-653. [PMID: 24088155 DOI: 10.1111/jlme.12074] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
The possibility that industry is exerting an undue influence on the culture of medicine has profound implications for the profession's public health mission. Policy analysts, investigative journalists, researchers, and clinicians have questioned whether academic-industry relationships have had a corrupting effect on evidence-based medicine. Psychiatry has been at the heart of this epistemic and ethical crisis in medicine. This article examines how commercial entities, such as pharmaceutical companies, influence psychiatric taxonomy and treatment guidelines. Using the conceptual framework of institutional corruption, we show that organized psychiatry's dependence on drug firms has led to a distortion of science. We describe the current dependency corruption and argue that transparency alone is not a solution. We conclude by taking the position that the corruption of the evidence base in diagnostic and practice guidelines has compromised the informed consent process, and we suggest strategies to address this problem.
Collapse
Affiliation(s)
- Lisa Cosgrove
- Associate Professor in the Department of Counseling and School Psychology at the University of Massachusetts Boston in Boston, MA. She is also a Lab Fellow at the Edmond J. Safra Center for Ethics at Harvard University in Cambridge, MA. Doctoral Student in the Department of Counseling and School Psychology at the University of Massachusetts Boston in Boston, MA
| | | |
Collapse
|
23
|
Mood and the Menstrual Cycle: A Review of Prospective Data Studies. ACTA ACUST UNITED AC 2012; 9:361-84. [PMID: 23036262 DOI: 10.1016/j.genm.2012.07.003] [Citation(s) in RCA: 59] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2012] [Revised: 07/06/2012] [Accepted: 07/11/2012] [Indexed: 11/21/2022]
|
24
|
W Freeman E. Treatment of depression associated with the menstrual cycle: premenstrual dysphoria, postpartum depression, and the perimenopause. DIALOGUES IN CLINICAL NEUROSCIENCE 2012. [PMID: 22033555 PMCID: PMC3181677 DOI: 10.31887/dcns.2002.4.2/efreeman] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Several forms of depression are unique to women because of their apparent association with changes in gonadal hormones, which in turn modulate neuroregulatory systems associated with mood and behavior. This review examines the evaluation and treatment of depression that occurs premenstrually, postpartum, or in the perimenopause on the basis of current literature. The serotonergic antidepressants consistently show efficacy for severe premenstrual syndromes (PMSs) and premenstrual dysphoric disorder (PMDD), and are the first-line treatment for these disorders. The use of antidepressants for postpartum depression is compromised by concerns for effects in the infants of breast-feeding mothers, but increasing evidence suggests the relative safety of the antidepressant medications, and the risk calculation should be made on an individual basis. Estradiol may be effective for postpartum depression and for moderate-to-severe major depression in the perimenopause. In spite of its frequent use, progesterone is not effective for the mood and behavioral symptoms of PMS/PMDD, postpartum depression, or perimenopausal depressive symptoms.
Collapse
Affiliation(s)
- Ellen W Freeman
- Research professor, Departments of Obstetrics/Gynecology and Psychiatry, University of Pennsylvania, Pa, USA
| |
Collapse
|
25
|
Lee EE, Nieman LK, Martinez PE, Harsh VL, Rubinow DR, Schmidt PJ. ACTH and cortisol response to Dex/CRH testing in women with and without premenstrual dysphoria during GnRH agonist-induced hypogonadism and ovarian steroid replacement. J Clin Endocrinol Metab 2012; 97:1887-96. [PMID: 22466349 PMCID: PMC3387419 DOI: 10.1210/jc.2011-3451] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
CONTEXT During conditions of ovarian suppression, women with premenstrual dysphoria (PMD) experience abnormal behavioral responses to physiological levels of ovarian steroids. Although hypothalamic-pituitary-adrenal (HPA) axis dysregulation frequently accompanies depression, and ovarian steroids regulate HPA axis responsivity, the role of HPA axis dysregulation in PMD is not known. We hypothesized that women with PMD would show abnormalities of HPA axis function analogous to those reported in depressive illness, and that ovarian steroids would differentially regulate HPA axis function in women with PMD compared with asymptomatic controls (AC). OBJECTIVE Our objective was to characterize the HPA axis response to physiological levels of estradiol and progesterone in women with PMD and AC. DESIGN AND SETTING We conducted an open-label trial of the GnRH agonist depot Lupron with ovarian steroid replacement administered in a double-blind crossover design in an outpatient clinic. PARTICIPANTS Forty-three women (18 with prospectively confirmed PMD and 25 AC) participated. INTERVENTIONS Women received Lupron for 6 months. After 3 months of hypogonadism, women received 5 wk each of estradiol (100-μg patch daily) or progesterone (suppositories 200 mg twice daily). During each condition, combined dexamethasone-suppression/CRH-stimulation tests and 24-h urinary free cortisol levels were performed. MAIN OUTCOME MEASURES Plasma cortisol and ACTH levels were evaluated. RESULTS HPA axis function was similar in PMD compared with AC. In all, progesterone significantly increased the secretion of cortisol compared with estradiol [area under the curve (t(74) = 3.1; P < 0.01)] and urinary free cortisol (t(74) = 3.2; P < 0.01) and ACTH compared with hypogonadism [area under the curve (t(74) = 2.4; P < 0.05)]. CONCLUSIONS HPA axis regulation is normal in PMD, suggesting that the pathophysiology of PMD differs from major depression. As observed previously, progesterone but not estradiol up-regulates HPA axis function in women.
Collapse
Affiliation(s)
- Ellen E Lee
- Section on Behavioral Endocrinology, National Institute of Mental Health, Bethesda, Maryland 20892-1277, USA
| | | | | | | | | | | |
Collapse
|
26
|
Reid RL. When should surgical treatment be considered for premenstrual dysphoric disorder? MENOPAUSE INTERNATIONAL 2012; 18:77-81. [PMID: 22611227 DOI: 10.1258/mi.2012.012009] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Premenstrual mood disorders afflict a substantial number of women of reproductive age. Medical treatments provide excellent symptomatic relief to many women but at times a poor therapeutic response or adverse effects attributable to these therapies lead women to seek alternative solutions. Oophorectomy (with concomitant hysterectomy) followed by low-dose estrogen therapy has been shown to be an effective alternative for such cases of menstrual-cycle-related mood disorder.
Collapse
Affiliation(s)
- Robert L Reid
- Division of Reproductive Endocrinology and Infertility, Queen’s University, Kingston, Ontario, K7L 2V7, Canada.
| |
Collapse
|
27
|
Epperson CN, Steiner M, Hartlage SA, Eriksson E, Schmidt PJ, Jones I, Yonkers KA. Premenstrual dysphoric disorder: evidence for a new category for DSM-5. Am J Psychiatry 2012; 169:465-75. [PMID: 22764360 PMCID: PMC3462360 DOI: 10.1176/appi.ajp.2012.11081302] [Citation(s) in RCA: 177] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Premenstrual dysphoric disorder, which affects 2%–5% of premenopausal women, was included in Appendix B of DSMIV, "Criterion Sets and Axes Provided for Further Study." Since then, aided by the inclusion of specific and rigorous criteria in DSM-IV, there has been an explosion of research on the epidemiology, phenomenology, pathogenesis, and treatment of the disorder. In 2009, the Mood Disorders Work Group for DSM-5 convened a group of experts to examine the literature on premenstrual dysphoric disorder and provide recommendations regarding the appropriate criteria and placement for the disorder in DSM-5. Based on thorough review and lengthy discussion, the work group proposed that the information on the diagnosis, treatment, and validation of the disorder has matured sufficiently for it to qualify as a full category in DSM-5. A move to the position of category, rather than a criterion set in need of further study, will provide greater legitimacy for the disorder and encourage the growth of evidence-based research, ultimately leading to new treatments.
Collapse
Affiliation(s)
- C Neill Epperson
- Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
| | | | | | | | | | | | | |
Collapse
|
28
|
Canning SE, Waterman MG, Simpson N, Dye L. Reliability and component structure of the modified Daily Symptom Report (DSR-20). J Affect Disord 2012; 136:612-9. [PMID: 22082685 DOI: 10.1016/j.jad.2011.10.021] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/29/2011] [Revised: 10/14/2011] [Accepted: 10/14/2011] [Indexed: 10/15/2022]
Abstract
OBJECTIVES The purpose of the present study was to modify Freeman et al.'s (1996) Daily Symptom Report (DSR) for premenstrual syndrome (PMS) by adding items depicting aggressive and impulsive symptoms, to explore the component structure of this revised measure (DSR-20) in a sample of PMS sufferers, and to compare their scores with those from controls during the follicular and luteal cycle phases. METHODS The DSR-20 was administered to 140 PMS sufferers who were seeking treatment for PMS and 54 controls who considered themselves to be free from premenstrual complaints daily for three menstrual cycles. RESULTS Cronbach's α was 0.95 for the luteal DSR-20 scores of the PMS sufferers, indicating very high internal consistency of the 20 items. Exploratory Principal Components Analysis (PCA) of the luteal ratings of the PMS sufferers identified two components with high internal consistency (>0.90), describing psychological and physical premenstrual symptoms. PMS sufferers scored significantly higher than the controls on each of these components during the luteal, but not follicular, phase. CONCLUSIONS The DSR-20 total scale score is an internally consistent global measure of the intensity of PMS. The division of PMS symptoms into psychological and physical components, both of which significantly differentiated PMS sufferers from controls during the luteal phase, sheds further light on the description of PMS and provides a clinically relevant and practical means by which to summarise and interpret daily symptom ratings, necessary for the identification and investigation of the syndrome.
Collapse
Affiliation(s)
- Sarah E Canning
- Division of Clinical Psychology, University of Manchester, UK.
| | | | | | | |
Collapse
|
29
|
Frye CA, Paris JJ, Walf AA, Rusconi JC. Effects and Mechanisms of 3α,5α,-THP on Emotion, Motivation, and Reward Functions Involving Pregnane Xenobiotic Receptor. Front Neurosci 2012; 5:136. [PMID: 22294977 PMCID: PMC3261425 DOI: 10.3389/fnins.2011.00136] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2011] [Accepted: 11/25/2011] [Indexed: 12/13/2022] Open
Abstract
Progestogens [progesterone (P(4)) and its products] play fundamental roles in the development and/or function of the central nervous system during pregnancy. We, and others, have investigated the role of pregnane neurosteroids for a plethora of functional effects beyond their pro-gestational processes. Emerging findings regarding the effects, mechanisms, and sources of neurosteroids have challenged traditional dogma about steroid action. How the P(4) metabolite and neurosteroid, 3α-hydroxy-5α-pregnan-20-one (3α,5α-THP), influences cellular functions and behavioral processes involved in emotion/affect, motivation, and reward, is the focus of the present review. To further understand these processes, we have utilized an animal model assessing the effects, mechanisms, and sources of 3α,5α-THP. In the ventral tegmental area (VTA), 3α,5α-THP has actions to facilitate affective, and motivated, social behaviors through non-traditional targets, such as GABA, glutamate, and dopamine receptors. 3α,5α-THP levels in the midbrain VTA both facilitate, and/or are enhanced by, affective and social behavior. The pregnane xenobiotic receptor (PXR) mediates the production of, and/or metabolism to, various neurobiological factors. PXR is localized to the midbrain VTA of rats. The role of PXR to influence 3α,5α-THP production from central biosynthesis, and/or metabolism of peripheral P(4), in the VTA, as well as its role to facilitate, or be increased by, affective/social behaviors is under investigation. Investigating novel behavioral functions of 3α,5α-THP extends our knowledge of the neurobiology of progestogens, relevant for affective/social behaviors, and their connections to systems that regulate affect and motivated processes, such as those important for stress regulation and neuropsychiatric disorders (anxiety, depression, schizophrenia, drug dependence). Thus, further understanding of 3α,5α-THP's role and mechanisms to enhance affective and motivated processes is essential.
Collapse
Affiliation(s)
- Cheryl A. Frye
- Department of Psychology, The University at Albany-SUNYAlbany, NY, USA
- Biological Sciences, The University at Albany-SUNYAlbany, NY, USA
- The Centers for Neuroscience, The University at Albany-SUNYAlbany, NY, USA
- Life Science Research, The University at Albany-SUNYAlbany, NY, USA
| | - J. J. Paris
- Department of Psychology, The University at Albany-SUNYAlbany, NY, USA
| | - A. A. Walf
- Life Science Research, The University at Albany-SUNYAlbany, NY, USA
| | - J. C. Rusconi
- Biological Sciences, The University at Albany-SUNYAlbany, NY, USA
| |
Collapse
|
30
|
Frye CA. Progesterone reduces depressive behavior of young ovariectomized, aged progestin receptor knockout, and aged wild type mice in the tail suspension test. J Psychopharmacol 2011; 25:421-8. [PMID: 19965943 PMCID: PMC3608207 DOI: 10.1177/0269881109349836] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Progestins may have effects to reduce depressive behavior, in part through actions of its metabolite, 5α-pregnan-3α-ol-20-one (3α,5α-THP) at GABA(A) receptors, rather than through intracellular progestin receptors. In this study, we examined the effects of progesterone (10 mg/kg, subcutaneous injection) versus vehicle control (propylene glycol) on the depressive behavior of young and aged mice in the tail suspension test. In Experiment 1, we first characterized progesterone's anti-depressant effects by utilizing young (4-6-month-old) intact or ovariectomized female, and intact or gonadectomized male, C57BL/6 mice. Young female mice showed more depressive behavior than the young male mice. Compared with vehicle administration, progesterone reduced depressive behavior of ovariectomized female, but not male or intact female mice. In Experiment 2, mice were aged (20-24-month-old) intact wild type or progestin receptor knockout mice. Progestin receptor knockout mice showed less depressive behavior than wild type mice. Administration of progesterone to wild type and progestin receptor knockout mice reduced depressive behavior. Together, these data suggest that progesterone can decrease depressive behavior of young adult ovariectomized female, aged wild type and progestin receptor knockout mice. Thus, progesterone's effect to reduce depressive behavior of aged mice may not require actions at the intracellular progestin receptors.
Collapse
Affiliation(s)
- Cheryl A Frye
- Department of Psychology and Biological Sciences, and Centers for Life Sciences and Neuroscience Research, University at Albany, SUNY, Albany, NY 12222, USA.
| |
Collapse
|
31
|
Fahs B. Sex during menstruation: Race, sexual identity, and women’s accounts of pleasure and disgust. FEMINISM & PSYCHOLOGY 2011. [DOI: 10.1177/0959353510396674] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
While much research has addressed negativity surrounding women’s menstruation, surprisingly little research has interrogated the relationship between menstruation and sexuality. This study used inductive thematic analysis of qualitative interviews with 40 women across a range of age, race and sexual orientation backgrounds to examine women’s experiences with sex during menstruation. Results showed that, while 25 women described negative reactions — and two described neutral reactions — 13 women described positive reactions to menstrual sex. Negative responses cohered around four themes: women’s discomfort and physical labor to clean ‘messes’, overt partner discomfort, negative self-perception and emotional labor to manage partner’s disgust. Positive responses cohered around two themes: physical and emotional pleasure from sex while menstruating, and rebellion against anti-menstrual attitudes. Notable race and sexual identity differences appeared, as white women and bisexual or lesbian-identified women described positive feelings about menstrual sex more than women of color or heterosexual women. Bisexual women with male partners described more positive reactions to menstrual sex than did heterosexual women with male partners, implying that heterosexual identity related to negative menstrual sex attitudes more than heterosexual behavior. Those with positive menstrual sex attitudes also enjoyed masturbation more than others. Implications for sexual identity and racial identity informing body practices, partner choice affecting women’s body affirmation, and women’s resistance against common cultural ideas about women’s bodies as ‘disgusting’ were addressed.
Collapse
Affiliation(s)
- Breanne Fahs
- Women and Gender Studies Program, Arizona State University, USA,
| |
Collapse
|
32
|
Bentz D, Steiner M, Meinlschmidt G. SIPS – Screening-Instrument für prämenstruelle Symptome*. DER NERVENARZT 2011; 83:33-9. [DOI: 10.1007/s00115-010-3210-6] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
33
|
Accortt EE, Stewart JL, Coan JA, Manber R, Allen JJ. Prefrontal brain asymmetry and pre-menstrual dysphoric disorder symptomatology. J Affect Disord 2011; 128:178-83. [PMID: 20833433 PMCID: PMC2994967 DOI: 10.1016/j.jad.2010.07.017] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/23/2010] [Revised: 07/01/2010] [Accepted: 07/17/2010] [Indexed: 11/30/2022]
Abstract
BACKGROUND Pre-menstrual dysphoric disorder (PMDD), a dysphoric form of pre-menstrual syndrome, is included as a diagnosis for further study in the DSM-IV-TR (APA, 2000). The present study investigated whether a marker of risk for major depressive disorder (MDD), prefrontal brain asymmetry, also characterizes women with PMDD. METHODS In a sample of 25 college women with PMDD symptomatology and 25 matched controls, resting frontal electroencephalographic (EEG) activity was assessed on four occasions within a two-week span. RESULTS Across several frontal sites women with PMDD had relatively less left than right prefrontal brain activity, consistent with a diathesis-stress model for menstrual-related dysphoria. CONCLUSIONS The findings suggest an overlap in the risk profile for MDD and PMDD.
Collapse
|
34
|
Pinkerton JV, Guico-Pabia CJ, Taylor HS. Menstrual cycle-related exacerbation of disease. Am J Obstet Gynecol 2010; 202:221-31. [PMID: 20207238 PMCID: PMC3107848 DOI: 10.1016/j.ajog.2009.07.061] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2009] [Revised: 07/13/2009] [Accepted: 07/23/2009] [Indexed: 10/19/2022]
Abstract
Exacerbation of common medical and mental health disorders at specific phases of the menstrual cycle is a prevalent phenomenon. Although the precise cause is unclear, studies implicate complex interactions between the immune and neuroendocrine systems. The menstrual cycle also is a trigger for the onset of depressive disorders, including premenstrual dysphoric disorder, a disorder specific to the luteal phase of the menstrual cycle, and depression associated with the transition to menopause. This article discusses common mental health problems exacerbated by the menstrual cycle, with a particular focus on premenstrual dysphoric disorder and perimenopausal depression. Throughout the reproductive lifespan, routine screening and assessment for the presence of common psychiatric disorders are critical for accurate diagnosis and provision of effective treatment. Management options include referral or consultation with a primary care provider or psychiatrist; treatment options for premenstrual dysphoric disorder and perimenopausal depression include pharmacotherapy with antidepressant agents and/or psychotherapy. Hormones may be helpful.
Collapse
Affiliation(s)
- Joann V Pinkerton
- Department of Obstetrics and Gynecology, University of Virginia, PO Box 801104, Northridge Ste. 104, Charlottesville, VA 22908, USA.
| | | | | |
Collapse
|
35
|
Histories of major depression and premenstrual dysphoric disorder: Evidence for phenotypic differences. Biol Psychol 2010; 84:235-47. [PMID: 20138113 DOI: 10.1016/j.biopsycho.2010.01.018] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2009] [Revised: 01/20/2010] [Accepted: 01/28/2010] [Indexed: 11/21/2022]
Abstract
This study examined unique versus shared stress and pain-related phenotypes associated with premenstrual dysphoric disorder (PMDD) and prior major depressive disorder (MDD). Sympathetic nervous system (SNS) and hypothalamic-pituitary-adrenal (HPA)-axis measures were assessed at rest and during mental stress, as well as sensitivity to cold pressor and tourniquet ischemic pain tasks in four groups of women: (1) non-PMDD with no prior MDD (N=18); (2) non-PMDD with prior MDD (N=9); (3) PMDD with no prior MDD (N=17); (4) PMDD with prior MDD (N=10). PMDD women showed blunted SNS responses to stress compared to non-PMDD women, irrespective of prior MDD; while women with prior MDD showed exaggerated diastolic blood pressure responses to stress versus never depressed women, irrespective of PMDD. However, only in women with histories of MDD did PMDD women have lower cortisol concentrations than non-PMDD women, and only in non-PMDD women was MDD associated with reduced cold pressor pain sensitivity. These results suggest both unique phenotypic differences between women with PMDD and those with a history of MDD, but also indicate that histories of MDD may have special relevance for PMDD.
Collapse
|
36
|
Dennerstein L, Lehert P, Bäckström TC, Heinemann K. Premenstrual symptoms -- severity, duration and typology: an international cross-sectional study. ACTA ACUST UNITED AC 2009; 15:120-6. [PMID: 19723682 DOI: 10.1258/mi.2009.009030] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
OBJECTIVES Determine women's experiences of premenstrual symptoms. STUDY DESIGN Cross-sectional survey. Sample In all, 4085 women aged 14-49 years recruited by random telephone digit dialing in France, Germany, Hungary, Italy, Spain, UK, Brazil and Mexico. Main outcome measures Telephone interview checklist of 23 premenstrual symptoms, sociodemographic variables and lifestyle variables. RESULTS The most prevalent symptoms were abdominal bloating, cramps or abdominal pain, breast tenderness, irritability and mood swings. Severity of symptoms is directly proportional to duration (R = 0.79). Hierarchical clustering found the following mental and physical domains and a typology: 'Mild' type (40.8%) with minimal symptoms; 'Moderate M' type (28.7%) with moderately severe, mostly mental symptoms; 'Moderate P' type (21.9%) with moderately severe, mostly physical symptoms; and 'Severe' type (8.6%) with severe intensity of both mental and physical symptoms. Multiple stepwise regression found significant effects on symptom duration severity index of age (linear and quadratic effects), current smoking and country. CONCLUSIONS Further research is needed on the impact of premenstrual symptoms on quality of life, and whether a brief symptom list could be developed as a valid and reliable tool globally.
Collapse
|
37
|
Neurosteroids' effects and mechanisms for social, cognitive, emotional, and physical functions. Psychoneuroendocrinology 2009; 34 Suppl 1:S143-61. [PMID: 19656632 PMCID: PMC2898141 DOI: 10.1016/j.psyneuen.2009.07.005] [Citation(s) in RCA: 71] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/15/2009] [Revised: 07/03/2009] [Accepted: 07/08/2009] [Indexed: 12/23/2022]
Abstract
Hormones are trophic factors that integrate central and peripheral nervous system functions, and can influence social, cognitive, emotional and physical (SCEP) processes. Greater understanding of behavioral and neurobiological underpinnings of mental, cognitive, and/or physical changes with maturation is becoming increasingly important as the world's population ages. There are individual differences in how people age, but the factors that influence these differences are not well understood. Social supports are one factor that may influence the trajectory of age-related processes. The loss of close relationships, especially among older persons, is one of the greatest risk factors for mental and physical decline. Progesterone, secreted by the ovaries, or produced de novo in the brain, is readily converted centrally to 5alpha-pregnan-3alpha-ol-20-one (3alpha,5alpha-THP), and can influence SCEP, through rapid, non-classical steroid-mediated actions. Our hypothesis is that 3alpha,5alpha-THP is a key trophic factor in SCEP and development. Our research has demonstrated that 3alpha,5alpha-THP facilitates social and sexual behavior of rodents, which evokes further increases in 3alpha,5alpha-THP in midbrain and hippocampus, brain areas involved in SCEP. The role of 3alpha,5alpha-THP to influence social and/or sexual experience, and thereby SCEP, is discussed in this review. Further understanding of these neurobiological and/or behavioral factors may lead to findings that ultimately can promote health and prevent disease.
Collapse
|
38
|
Smith SS, Aoki C, Shen H. Puberty, steroids and GABA(A) receptor plasticity. Psychoneuroendocrinology 2009; 34 Suppl 1:S91-S103. [PMID: 19523771 PMCID: PMC2794901 DOI: 10.1016/j.psyneuen.2009.05.011] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/29/2009] [Revised: 04/27/2009] [Accepted: 05/19/2009] [Indexed: 11/17/2022]
Abstract
GABA(A) receptors (GABAR) mediate most inhibition in the CNS and are also a target for neuroactive steroids such as 3alpha,5[alpha]beta-THP (3alphaOH-5[alpha]beta-OH-pregnan-20-one or [allo]pregnanolone). Although these steroids robustly enhance current gated by alpha1beta2delta GABAR, we have shown that 3alpha,5[alpha]beta-THP effects at recombinant alpha4beta2delta GABAR depend on the direction of Cl(-) flux, where the steroid increases outward flux, but decreases inward flux through the receptor. This polarity-dependent inhibition of alpha4beta2delta GABAR resulted from an increase in the rate and extent of rapid desensitization of the receptor, recorded from recombinant receptors expressed in HEK-293 cells with whole cell voltage clamp techniques. This inhibitory effect of 3alpha,5[alpha]beta-THP was not observed at other receptor subtypes, suggesting it was selective for alpha4beta2delta GABAR. Furthermore, it was prevented by a selective mutation of basic residue arginine 353 in the intracellular loop of the receptor, suggesting that this might be a putative chloride modulatory site. Expression of alpha4betadelta GABAR increases markedly at extrasynaptic sites at the onset of puberty in female mice. At this time, 3alpha,5[alpha]beta-THP decreased the inhibitory tonic current, recorded with perforated patch techniques to maintain the physiological Cl(-) gradient. By decreasing this shunting inhibition, 3alpha,5[alpha]beta-THP increased the excitability of CA1 hippocampal pyramidal cells at puberty. These effects of the steroid were opposite to those observed before puberty when 3alpha,5[alpha]beta-THP reduced neuronal excitability as a pre-synaptic effect. Behaviorally, the excitatory effect of 3alpha,5[alpha]beta-THP was reflected as an increase in anxiety at the onset of puberty in female mice. Taken together, these findings suggest that the emergence of alpha4beta2delta GABAR at the onset of puberty reverses the effect of a stress steroid. These findings may be relevant for the mood swings and increased response to stressful events reported in adolescence.
Collapse
Affiliation(s)
- Sheryl S Smith
- Department of Physiology and Pharmacology, SUNY Downstate Medical Center, 450 Clarkson Ave., Brooklyn, NY 11203, USA.
| | | | | |
Collapse
|
39
|
Miller LJ, Girgis C, Gupta R. Depression and Related Disorders during the Female Reproductive Cycle. WOMENS HEALTH 2009; 5:577-87. [DOI: 10.2217/whe.09.44] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
For some women, times of reproductive transition represent times of high risk for the onset or exacerbation of depressive symptoms. In order to maintain emotional stability, the female brain must adapt to fluctuations in hormones that affect neurotransmitter functioning. Difficulty with this adaptation, along with stresses related to social role transitions, may confer heightened vulnerability to depression. In this review, we summarize data regarding the course, expression and risks of depression and related symptoms during puberty and menarche, the luteal phase of the menstrual cycle, the perinatal period and perimenopause. We note treatment strategies that have been found to be effective for depressive symptoms during specific phases of the female reproductive cycle.
Collapse
Affiliation(s)
- Laura J Miller
- Laura J Miller, MD, Vice Chair for Academic Clinical Services Director, Women's Mental Health, Department of Psychiatry, Brigham & Women's Hospital/Faulkner Hospital, 75 Francis Street, Boston, MA 02115, USA, Tel.: +1 617 525 7469,
| | - Christina Girgis
- Christina Girgis, MD, Department of Veteran Affairs, Edward Hines, Jr. Hospital, P.O. Box 5000, Hines, IL 60141, USA
| | - Renu Gupta
- Renu Gupta, MD, Department of Psychiatry, University of Illinois at Chicago, 912 S. Wood Street, M/C 913, Chicago, IL 60612, USA, Tel.: +1 312 996 4685, Fax: +1 312 355 1095,
| |
Collapse
|
40
|
Abstract
Drospirenone is a novel progestogen that possesses antimineralocorticoid activity. This activity is seen clinically in its effects on physiological parameters, body weight, general well-being and fluid-related symptoms. Clinical studies with an oral contraceptive containing 30 microg ethinylestradiol and 3 mg drospirenone (Yasmin, Schering AG, Berlin, Germany) and a new continuous combined oral hormone replacement therapy (HRT) containing 1 mg 17beta-estradiol and 2 mg drospirenone (Angeliq, Schering AG) were all designed specifically to evaluate treatment effects on body weight and cardiovascular function, both of which can be influenced by aldosterone receptor antagonism. Weight gain during traditional oral contraceptive and HRT use has been one of the main reasons for poor compliance and discontinuation. Women receiving hormone therapy with 1 mg 17beta-estradiol/2 mg drospirenone had either no weight change or a small decrease, while those receiving estradiol alone tended to increase in weight. Mean body weight after 1 year of treatment with 1 mg 17beta-estradiol/2 mg drospirenone decreased by 1.2 kg (p < 0.001). Studies using different drospirenone doses in combination with estradiol indicate that the effect on body weight is dependent on the dose of drospirenone, and that this is due to drospirenone's antimineralocorticoid activity. These data are in agreement with previous studies that compared the changes in body weight in young women receiving for 13 or 26 cycles the oral contraceptives 30 microg ethinylestradiol/3 mg drospirenone or 30 microg ethinylestradiol/150 microg desogestrel (Marvelon, Organon International); 30 microg ethinylestradiol/3 mg drospirenone had a more favorable effect on body weight, with the mean body weight remaining lower than baseline for the majority of women. A variety of physical and emotional changes have been linked to hormonal fluctuations during the menstrual cycle. Fluid retention-related symptoms, such as breast tenderness, swelling, abdominal bloating and skin changes, may affect well-being and quality of life. Improvements in these cycle-dependent disorders, together with some psychological symptoms, such as fatigue and depressive mood, are well documented with the use of 30 microg ethinylestradiol/3 mg drospirenone. Therefore, the effects of hormone therapy with 1 mg 17beta-estradiol/2 mg drospirenone on quality of life were assessed in the Women's Health Questionnaire. Significant improvements were observed in quality of life during treatment with 1 mg 17beta-estradiol/2 mg drospirenone, which also resulted in higher mean scores than estradiol alone. Improvements were mainly seen in somatic symptoms, anxiety/fears and cognitive difficulties.1 mg 17beta-estradiol/2 mg drospirenone has unique antimineralocorticoid properties, which can be attributed to drospirenone. This combination prevents salt and water retention elicited by estrogens, and thereby prevents increases in blood pressure and maintains a stable body weight. Its additional beneficial impact on premenstrual symptomatology and health-related quality of life may improve well-being and clinical tolerance.
Collapse
Affiliation(s)
- J-M Foidart
- Department of Gynecology and Obstetrics, University of Liège, Belgium
| |
Collapse
|
41
|
|
42
|
Miller MN, Newell CL, Miller BE, Frizzell PG, Kayser RA, Ferslew KE. Variable dosing of sertraline for premenstrual exacerbation of depression: a pilot study. J Womens Health (Larchmt) 2008; 17:993-7. [PMID: 18681820 DOI: 10.1089/jwh.2007.0491] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
OBJECTIVES Premenstrual exacerbation of depression (PMED) is a variation of major depressive disorder (MDD) in which symptoms worsen during the premenstrual period. Breakthrough symptoms of PMED may occur despite effective antidepressant treatment in the rest of the cycle. This pilot study is designed to evaluate the effectiveness of variable dosing in PMED using the antidepressant sertraline. METHODS Women diagnosed with PMED were started on sertraline (up to 50 or 100 mg/day). Those subjects demonstrating continued PMED on a constant dose (n = 9) were entered into a double-blind crossover protocol, receiving either placebo or an increase in sertraline premenstrually. Each subject was evaluated twice a month (follicular and luteal phase) by clinical evaluation, Beck Depression Inventory (BDI), Hamilton Depression Rating Scale (HAM-D), and daily symptom diary and had blood collected for sertraline assay. RESULTS Use of variable dosing resolved the PMED, such that there was no longer a significant difference in scores for the BDI and the HAM-D between the luteal and follicular phases during treatment with sertraline supplement (p = 0.32 and p = 0.53, paired t test, respectively). However, during the months with placebo supplement, the luteal and follicular phases showed a trend for differences for the BDI (p = 0.06, paired t test) and significant differences for the HAM-D (p = 0.02 paired t test); that is, the subjects retained the PMED pattern. Sertraline levels reflected the change in dosing pattern, with higher levels seen during the luteal phase during the months with sertraline supplement but no difference seen between luteal and follicular phases during months with placebo supplement (p = 0.07 and 0.69, paired t test, respectively). CONCLUSIONS The use of variable dosing in PMED increases the effectiveness of treatment.
Collapse
Affiliation(s)
- Merry Noel Miller
- Department of Psychiatry and Behavioral Sciences, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, Tennessee 37614, USA.
| | | | | | | | | | | |
Collapse
|
43
|
Franklin TR, Ehrman R, Lynch KG, Harper D, Sciortino N, O'Brien CP, Childress AR. Menstrual cycle phase at quit date predicts smoking status in an NRT treatment trial: a retrospective analysis. J Womens Health (Larchmt) 2008; 17:287-92. [PMID: 18321180 DOI: 10.1089/jwh.2007.0423] [Citation(s) in RCA: 72] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND AND OBJECTIVE The deleterious health consequences of smoking are even more severe for women, yet ironically, they have more difficulty quitting than men. Identifying relapse predictors for women and implementing strategies to increase their chances of successfully quitting and remaining abstinent are important goals. Clinicians and researchers suggest that women could achieve greater success in smoking cessation interventions if the initial quit attempt coincided with the follicular phase (i.e., preovulatory phase) of their menstrual cycle (MC) rather than the luteal phase (i.e., premenstrual). However, no experimental data have been published to support this claim. Our objective was to determine whether MC phase affected smoking status in premenopausal female smokers participating in a smoking cessation treatment trial. METHODS Data from 102 treatment-seeking smokers who participated in an 8-week nicotine replacement therapy (NRT) plus behavioral intervention smoking cessation study were examined retrospectively. NRT began the day subjects attempted to quit smoking (quit date). For analyses, smokers were grouped according to sex, and women were subdivided by MC phase at quit date into follicular (FF, days 1-14, n = 16) and luteal (LF, days 15-30, n = 21) groups. RESULTS Smoking status was examined on the third day after the quit date (day 3) and at 1 week posttreatment (week 9). On day 3, 52% of LFs reported smoking compared with 19% of FFs (p < 0.04), and at week 9, 71% of LFs reported smoking compared with 31% of FFs (p < 0.02). In a comparison group of men (n = 65), 25% were smoking at day 3 and 68% at week 9. Self-report at week 9 was verified by urine cotinine levels. CONCLUSIONS These data support the supposition that better treatment outcomes can be achieved by scheduling quit dates to coincide with the follicular phase of the MC in female smokers.
Collapse
Affiliation(s)
- Teresa R Franklin
- Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6178, USA.
| | | | | | | | | | | | | |
Collapse
|
44
|
Yang M, Wallenstein G, Hagan M, Guo A, Chang J, Kornstein S. Burden of premenstrual dysphoric disorder on health-related quality of life. J Womens Health (Larchmt) 2008; 17:113-21. [PMID: 18240988 DOI: 10.1089/jwh.2007.0417] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
OBJECTIVE The purpose of this study was to document the burden of premenstrual dysphoric disorder (PMDD) on health-related quality of life (HRQoL) in comparison to the U.S. general population and specific chronic health conditions. METHODS The disease burden that PMDD placed on HRQoL was estimated by comparing SF-12v2 scores between women who were identified as being at risk for PMDD with those observed in the general U.S. female population. Additional comparisons were made to several chronic health conditions. Regression methods were used to estimate SF-12v2 normative values from the general population sample and statistically adjust them to match age and the presence of disease comorbidity of the PMDD patient group. Significance tests were used to compare the means across samples. RESULTS After adjusting for multiple comparisons, six SF-12v2 scales and two summary measures of PMDD were significantly below the adjusted U.S. general population norms. Both summary measures of PMDD had mean differences greater than 3 points below the norm (threshold for clinical meaningful difference). The burden of PMDD was greater on mental/emotional HRQoL domains than on physical HRQoL. The HRQoL burden of PMDD was (1) greater than that of chronic back pain in bodily pain and mental health (MH) scales and greater than type 2 diabetes and hypertension in bodily pain scale while comparable in all other scales of the three conditions, (2) comparable to osteoarthritis and rheumatoid arthritis in all scales, and (3) less burden than depression in vitality and MH scales and mental component summary measure while comparable in other scales. CONCLUSIONS PMDD is associated with substantial burden on both physical and mental aspects of HRQoL.
Collapse
Affiliation(s)
- Min Yang
- QualityMetric Inc., Lincoln, Rhode Island 02865, USA.
| | | | | | | | | | | |
Collapse
|
45
|
Reinhard-Hennch B, Strowitzki T. Vitamin B6 bei prämenstruellem Syndrom. GYNAKOLOGISCHE ENDOKRINOLOGIE 2008. [DOI: 10.1007/s10304-008-0260-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
46
|
Knaapen L, Weisz G. The biomedical standardization of premenstrual syndrome. STUDIES IN HISTORY AND PHILOSOPHY OF BIOLOGICAL AND BIOMEDICAL SCIENCES 2008; 39:120-134. [PMID: 18331959 DOI: 10.1016/j.shpsc.2007.12.009] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/15/2007] [Revised: 09/10/2007] [Indexed: 05/26/2023]
Abstract
This essay traces the history of premenstrual syndrome (PMS) in French, British, and American medical literature from 1950 to 2004. Aetiological theories, treatments and diagnostic criteria have varied over time and place, reflecting local conditions and changing notions of objectivity and evidence. During the 1970s researchers in each nation utilised different research strategies to overcome variation and contradictory results characteristic of PMS research. Since the 1980s, attempts have been made to standardise research internationally through prospective daily rating questionnaires that diagnose and measure PMS. Amidst controversy, a psychiatric reformulation of the syndrome was included in the Diagnostic and Statistical Manual of Mental Disorders (DSM). While the diagnostic criteria for this psychiatric category, now called premenstrual dysphoric disorder (PMDD), are widely accepted for research purposes, efforts to transfer them to medical practice have been less successful. PMDD remains a contested disease construct.
Collapse
Affiliation(s)
- Loes Knaapen
- Department of Social Studies of Medicine, McGill University, Montreal, Quebec H3A 1X1, Canada.
| | | |
Collapse
|
47
|
Smith SS, Shen H, Gong QH, Zhou X. Neurosteroid regulation of GABA(A) receptors: Focus on the alpha4 and delta subunits. Pharmacol Ther 2007; 116:58-76. [PMID: 17512983 PMCID: PMC2657726 DOI: 10.1016/j.pharmthera.2007.03.008] [Citation(s) in RCA: 168] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2007] [Accepted: 03/29/2007] [Indexed: 11/24/2022]
Abstract
Neurosteroids, such as the progesterone metabolite 3alpha-OH-5alpha[beta]-pregnan-20-one (THP or [allo]pregnanolone), function as potent positive modulators of the GABA(A) receptor (GABAR) when acutely administered. However, fluctuations in the circulating levels of this steroid at puberty, across endogenous ovarian cycles, during pregnancy or following chronic stress produce periods of prolonged exposure and withdrawal, where changes in GABAR subunit composition may occur as compensatory responses to sustained levels of inhibition. A number of laboratories have demonstrated that both chronic administration of THP as well as its withdrawal transiently increase expression of the alpha4 subunit of the GABAR in several areas of the central nervous system (CNS) as well as in in vitro neuronal systems. Receptors containing this subunit are insensitive to benzodiazepine (BDZ) modulation and display faster deactivation kinetics, which studies suggest underlie hyperexcitability states. Similar increases in alpha4 expression are triggered by withdrawal from other GABA-modulatory compounds, such as ethanol and BDZ, suggesting a common mechanism. Other studies have reported puberty or estrous cycle-associated increases in delta-GABAR, the most sensitive target of these steroids which underlies a tonic inhibitory current. In the studies reported here, the effect of steroids on inhibition, which influence anxiety state and seizure susceptibility, depend not only on the subunit composition of the receptor but also on the direction of Cl(-) current generated by these target receptors. The effect of neurosteroids on GABAR function thus results in behavioral outcomes relevant for pubertal mood swings, premenstrual dysphoric disorder and catamenial epilepsy, which are due to fluctuations in endogenous steroids.
Collapse
Affiliation(s)
- Sheryl S Smith
- Department of Physiology and Pharmacology, SUNY Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, NY 11203, USA.
| | | | | | | |
Collapse
|
48
|
Qiao M, Zhao Q, Zhang H, Wang H, Xue L, Wei S. Isolating with physical restraint low status female monkeys during luteal phase might make an appropriate premenstrual depression syndrome model. J Affect Disord 2007; 102:81-91. [PMID: 17258814 DOI: 10.1016/j.jad.2006.12.011] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/11/2006] [Revised: 12/13/2006] [Accepted: 12/13/2006] [Indexed: 12/14/2022]
Abstract
BACKGROUND Rhesus monkeys (Macaca mulatta) have a close phylogenetic relationship to humans, and have a similar 28-day menstrual cycle with similar hormonal fluctuations. In this study, we attempt to establish the premenstrual depression syndrome of rhesus monkey (M. mulatta) models by isolation with physical restraint of low social status young female monkeys during their luteal phase. METHODS Low social status young female rhesus monkeys (M. mulatta) were isolated with physical restraint during their luteal phase by using a specifically designed isolating-cage. During the entire menses cycle, serum levels of 5-hydroxytrypamine, noradrenalin and adrenalin were detected by capillary zone electrophoresis, and the changes in the serum levels of progesterone, estradiol and prolactin were investigated by radioimmunoassay. At the same time, the pharmaceutical interference effect of Jingqianshu granule, a traditional Chinese medicine specifically used to cure premenstrual depression patients, was tested using this premenstrual depression syndrome monkey model. RESULTS After being immured in two consecutive menstrual cycles, monkeys presented depressive symptoms during the premenstrual phase of three consecutive menstrual cycles. The serum contents of the three kinds of monoamine neurotransmitters in depressive monkeys were significantly higher than the normal ones. The serum levels of progesterone and prolactin increased obviously, and a marked change in the pattern of progesterone secretion could be observed. Moreover, the premenstrual depressive symptoms of model group monkeys could not only be cured by Jingqianshu granule, but the higher serum levels of prolactin and monoamine neurotransmitters in these monkeys could be reduced by this herbal medicine. These data were well in line with clinical observations of women with premenstrual depression syndrome. CONCLUSION Our results in this study for the first time indicate that isolation with physical restraint of low status young female monkeys during their luteal phase makes an appropriate premenstrual depression syndrome model. This model might potentially facilitate studies on the etiology of premenstrual depression syndrome and the development of better methods for the therapy of this disease.
Collapse
Affiliation(s)
- Mingqi Qiao
- Institute of Traditional Chinese Medicine theory, School of Basic Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250014, China.
| | | | | | | | | | | |
Collapse
|
49
|
Nur MM, Romano ME, Siqueira LM. Premenstrual dysphoric disorder in an adolescent female. J Pediatr Adolesc Gynecol 2007; 20:201-4. [PMID: 17561191 DOI: 10.1016/j.jpag.2006.09.014] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/15/2006] [Revised: 08/28/2006] [Accepted: 09/01/2006] [Indexed: 11/18/2022]
Abstract
BACKGROUND A severe cyclic constellation of affective symptoms during the luteal phase of the menstrual cycle is termed premenstrual dysphoric disorder (PMDD). CASE A 17-yr-old female was referred for evaluation of behavior changes with her menses. Parents noted behavior changes, two to three days before the onset and lasting till the end of her menses. Menarche was at 13 years. Periods were regular, with normal flow and duration and no dysmenorrhea. Psychosocial history was unremarkable. There was no history of sexual activity or abuse. Her physical exam was unremarkable. With the working diagnosis of premenstrual dysphoric syndrome she was asked to keep track of her menses on a menstrual calendar and her symptoms with a daily diary. She was treated with Fluoxetine 20 mg/day during the luteal phase of her menstrual cycle with complete resolution of her symptoms. COMMENTS In PMDD the mood disturbance occurs during the late luteal phase of the menstrual cycle (approximately 1 week before the onset of menstrual bleeding), remits after the onset of menses, and can be established by a prospective daily symptom log for two consecutive cycles. The symptoms are more severe than that of premenstrual syndrome, are associated with significant functional impairment and are cyclical. Symptoms were documented prospectively as starting a few days before her menstrual bleeding and remitting at the end of it. She responded to episodic use of a selective serotonin reuptake inhibitor. This disorder needs to be better recognized, because it can be easily treated.
Collapse
Affiliation(s)
- Marcela M Nur
- Division of Adolescent Medicine, Miami Children's Hospital, Miami, Florida 33155, USA.
| | | | | |
Collapse
|
50
|
Smith SS, Gong QH. Ethanol effects on GABA-gated current in a model of increased alpha4betadelta GABAA receptor expression depend on time course and preexposure to low concentrations of the drug. Alcohol 2007; 41:223-31. [PMID: 17591545 PMCID: PMC2658629 DOI: 10.1016/j.alcohol.2007.04.007] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2007] [Revised: 04/17/2007] [Accepted: 04/17/2007] [Indexed: 01/28/2023]
Abstract
Several recent studies have suggested that alphabetadelta subtypes of gamma-aminobutyric acid type A (GABAA) receptors (delta-GABAR) are a target for low dose ethanol (<30 mM). However, there are also conflicting reports suggesting that only high doses of the drug (100 mM) modulate these receptors. In addition, the studies which have demonstrated a clear effect of low dose ethanol on delta-GABAR find different effective concentrations for this effect. Here, we test the hypothesis that the apparent disparity in effective concentration is due to time-course effects when low (1-3 mM) dose ethanol is preapplied. To this end, we tested ethanol effects on native GABAR in CA1 hippocampus in a model of increased alpha4betadelta GABAR expression following 48h administration of the GABA-modulatory steroid THP (3alpha-OH-5beta-pregnan-20-one) to adult, female rats. GABA(EC20)-gated current was recorded with whole-cell patch clamp procedures from acutely isolated pyramidal cells. We assessed ethanol's effect on GABA-gated current using either (1) 2-5 min application of ethanol in increasing concentrations (0.1-30 mM) or (2) coadministration of ethanol with GABA. Two minute application of 1-3 mM ethanol produced optimal potentiation of GABA-gated current following steroid treatment, with higher concentrations less effective. In contrast, 30 mM ethanol produced optimal effects when ethanol was not preapplied. However, following preapplication of 1mM ethanol, 30 mM ethanol decreased the peak GABA-gated current. These findings suggest that ethanol may act at multiple interacting sites to affect GABAR efficacy and desensitization. These data also suggest that ethanol effects on GABA-gated current are affected by the time course of exposure and previous exposure to low concentrations of the drug.
Collapse
Affiliation(s)
- Sheryl S Smith
- Department of Physiology and Pharmacology, Box 31, SUNY Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, NY 11203, USA.
| | | |
Collapse
|